Clinical Trial Shows Daraxonrasib Doubles Survival Time for Advanced Pancreatic Cancer Patients
A clinical trial has revealed that a daily pill, daraxonrasib, can significantly extend the survival time for patients with advanced pancreatic cancer. The trial, involving 500 patients, demonstrated that those who took daraxonrasib lived an average of 13.2 months, compared to 6.6 to 6.7 months for those undergoing chemotherapy. This drug targets the Kras protein, which is involved in the growth of nearly all pancreatic cancers. The findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago, where experts hailed the drug as a 'gamechanger' in cancer treatment. The trial was led by researchers at the Dana-Farber Cancer Institute in Boston. 
